Journal: Cell reports
Article Title: TLR9 Sensing of Self-DNA Controls Cell-Mediated Immunity to Listeria Infection via Rapid Conversion of Conventional CD4 + T Cells to T reg
doi: 10.1016/j.celrep.2020.01.040
Figure Lengend Snippet: (A) C57BL/6 mice administered 50 μg CpG-A, CpG-B, and CpG control ODNs at days −1 and 0. Frequency of splenic CD25 + FoxP3 + CD4 + T reg and change in FoxP3 + :FoxP3 − CD4 + T cell ratio relative to CpG controls (D FoxP3 + :FoxP3 − ) at day 1 (n = 4 per group). (B) C57BL/6 and Foxp3 DTR-EGFP mice administered CpG ODNs as in (A) and infected with LD Lm Δ actA -Ova at day 0 and co-delivered a complete DT regimen. Absolute number of splenic Ova-specific CD8 + T cells at day 7 post-infection (n = 6 per group). (C) Splenic Ova-specific CD8 + T cell response observed in CpG-treated or -infected C57BL/6 as in (B), with blockade of IL-12 (p70) (n = 4 per group). (D) Quantification of mtDNA ( 12 s and Trlev ), nDNA ( Neb and Becn1 ), and Lm DNA ( Ova , mpl , and plcB ) in cell- and RNA-free serum samples after HD Lm Δ actA - Ova infection of C57BL/6 mice (n = 6 per group). (E) Serum ALT concentration within LD versus HD Lm Δ actA -Ova-infected C57BL/6 mice (n = 6 per group). (F) Effect of neutrophil depletion before HD Lm Δ actA -Ova infection of C57BL/6 mice on mtDNA ( 12 s and Trlev ) in cell- and RNA-free serum samples isolated at 4 h post-infection (n = 6 per group). (G) Absolute number of splenic Ova-specific CD8 + T cells at day 7 post-infection in C57BL/6 and Foxp3 DTR-EGFP mice administered a complete DT regimen, systemic HD Lm Δ actA -Ova, and selective DNase I delivery (n = 4 per group). (H) Survival of untreated versus DNase I-treated C57BL/6 mice infected with WT Lm Ova (n = 10–16 per group). (I and J) In vitro co-expression of FoxP3 and T-bet in conventional CD4 + EGFP − T cells isolated from Foxp3 EGFP or Il12rb2 −/− Foxp3 EGFP mice cultured in the presence or absence of CD3/CD28-mediated activation, rmTGF-b1, and rmIL-12 (p70) (n = 4 per group).
Article Snippet: ant-IL-12 (p70) (R2-9A5) , BioXCell , Cat#BE0233.
Techniques: Control, Infection, Concentration Assay, Isolation, In Vitro, Expressing, Cell Culture, Activation Assay